Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
04. März 2021 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
25. Februar 2021 09:07 ET
|
Akari Therapeutics Plc
A newly published review article in the journal CELLS highlights the role LTB4 plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye. Elevated...
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
01. Februar 2021 09:29 ET
|
Akari Therapeutics Plc
Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing on new clinical targets.Votucalis...
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
06. Januar 2021 09:32 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
11. Dezember 2020 09:00 ET
|
Akari Therapeutics Plc
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European...
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
11. Dezember 2020 08:55 ET
|
Akari Therapeutics Plc
New data accrued from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence. Transfusion...
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
03. Dezember 2020 10:00 ET
|
Akari Therapeutics Plc
New data highlight role of leukotriene B4 (LTB4) in the pathophysiology of retinal inflammation and degenerationIn the experimental allergic uveitis (EAU) disease model nomacopan reduced Th17 effector...
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
27. Oktober 2020 09:00 ET
|
Akari Therapeutics Plc
Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BPThe Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to...
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
06. Oktober 2020 08:30 ET
|
Akari Therapeutics Plc
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior expanded access programFollowing initial proof of...
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
01. Oktober 2020 09:00 ET
|
Akari Therapeutics Plc
The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients with a primary endpoint of disease...